Ahmed S. Eltawel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ahmed S. Eltawel has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aboubaker M. Saleh
Faculty of Medicine, Cairo University, Cairo, Egypt, Egypt
1 shared publication - Amani Nabil Shafik
Medical Pharmacology Department, Faculty of Medicine, Cairo University, Cairo, Egypt and School of Medicine, Badya University, Giza, Egypt, Egypt
1 shared publication - Fady A. Iskander
School of Medicine, Badya University, Giza, Egypt, Egypt
1 shared publication - Gehad S. Ahmed
Medical Pharmacology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Egypt
1 shared publication - Hanaa S. Sallam
Department of Population Health and Health Disparities, Division of Global Partnerships, School of Public and Population Health, University of Texas Medical Branch at Galveston, Galveston, USA
1 shared publication - Hani Serag
Department of Population Health and Health Disparities, School of Public and Population Health, University of Texas Medical Branch, Galveston, TX 77555, USA
1 shared publication
Latest Publications
- Open Access
- 3 March 2026
- Published by MDPI AG in Preprints.org
Efficacy and Safety of Dexmedetomidine in the Prevention of Delirium in Intensive Care Units and Critically-Ill Old Adult Patients: A Systematic Review
Background/Objectives: Delirium is an acute state of confusion associated with impaired consciousness and a decline in cognitive function. Delirium has significant clinical importance due to its substantial impact on morbidity and mortality. The primary objective of this systematic review is to assess Dexmedetomidine’s potential efficacy for delirium in critically ill and elderly patients, addressing a significant need in this high-risk population, and to evaluate its safety as a secondary objective. Methods: A systematic review (2018–2024) searched PubMed, Embase, and Cochrane for English-language studies on dexmedetomidine and delirium in older intensive care unit (ICU) patients. Dual reviewers independently screened, extracted data, and resolved disagreements. Eligible randamized control trials (RCTs) and observational studies were assessed using Risk of Bias 2 ( RoB-2) and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tools. Results: Dexmedetomidine emerges as a promising drug because of its unique pharmacological profile, which provides sedation without modulating gamma-aminobutyric acid (GABA) receptors, potentially lowering the risk of delirium. Its additional analgesic, anti-inflammatory, and organ-protective characteristics could provide broader clinical benefits in the ICU. However, the aged population’s heightened susceptibility to Dexmedetomidine’s hemodynamic effects may limit some of its potential benefits. Conclusions: Although existing research suggests short-term neuroprotective effects, these effects do not always translate into better long-term survival. As a result, further large-scale, well-designed randomized controlled trials are needed to determine the optimal use of Dexmedetomidine in this population and to understand its overall impact on morbidity and mortality in the ICU.
- 3 March 2026
- Published by MDPI AG in Preprints.org
Open AccessEfficacy and Safety of Dexmedetomidine in the Prevention of Delirium in Intensive Care Units and Critically-Ill Old Adult Patients: A Systematic Review
Background/Objectives: Delirium is an acute state of confusion associated with impaired consciousness and a decline in cognitive function. Delirium has significant clinical importance due to its substantial impact on morbidity and mortality. The primary objective of this systematic review is to assess Dexmedetomidine’s potential efficacy for delirium in critically ill and elderly patients, addressing a significant need in this high-risk population, and to evaluate its safety as a secondary objective. Methods: A systematic review (2018–2024) searched PubMed, Embase, and Cochrane for English-language studies on dexmedetomidine and delirium in older intensive care unit (ICU) patients. Dual reviewers independently screened, extracted data, and resolved disagreements. Eligible randamized control trials (RCTs) and observational studies were assessed using Risk of Bias 2 ( RoB-2) and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tools. Results: Dexmedetomidine emerges as a promising drug because of its unique pharmacological profile, which provides sedation without modulating gamma-aminobutyric acid (GABA) receptors, potentially lowering the risk of delirium. Its additional analgesic, anti-inflammatory, and organ-protective characteristics could provide broader clinical benefits in the ICU. However, the aged population’s heightened susceptibility to Dexmedetomidine’s hemodynamic effects may limit some of its potential benefits. Conclusions: Although existing research suggests short-term neuroprotective effects, these effects do not always translate into better long-term survival. As a result, further large-scale, well-designed randomized controlled trials are needed to determine the optimal use of Dexmedetomidine in this population and to understand its overall impact on morbidity and mortality in the ICU.